Chronic immune checkpoint inhibitor pneumonitis

BACKGROUND: Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks of corticosteroid therapy. Herein, we report...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Naidoo, Jarushka, Cottrell, Tricia R, Lipson, Evan J, Forde, Patrick M, Illei, Peter B, Yarmus, Lonny B, Voong, K Ranh, Feller-Kopman, David, Lee, Hans, Riemer, Joanne, Wang, Daphne, Taube, Janis M, Brahmer, Julie R, Lin, Cheng Ting, Danoff, Sonye K, D'Alessio, Franco R, Suresh, Karthik
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Short Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7304886/
https://ncbi.nlm.nih.gov/pubmed/32554618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000840
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы